Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)

被引:50
作者
Gonder, John R. [1 ]
Walker, Valery M. [2 ]
Barbeau, Martin [3 ]
Zaour, Nancy [3 ]
Zachau, Bryan H. [2 ]
Hartje, James R. [2 ]
Li, Ruihong [3 ]
机构
[1] Ivey Eye Inst, St Josephs Hlth Ctr, London, ON N6A 4V2, Canada
[2] OptumInsight, Burlington, ON L7L 6W6, Canada
[3] Novartis Pharmaceut Canada, Dorval, PQ H9S 1A9, Canada
关键词
RETINOPATHY; DEGENERATION;
D O I
10.1155/2014/939315
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. To characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients. Patients and Methods. 145 patients with DME were followed for 6 months with monthly telephone interviews and medical chart reviews at months 0, 3, and 6. Visual acuity in the worst-seeing eye was assessed at months 0 and 6. DME-related healthcare costs were determined over 6 months, and vision-related (National Eye Institute Visual Functioning Questionnaire) and generic (EQ-5D) quality of life was assessed at months 0, 3, and 6. Results. Mean age of patients was 63.7 years: 52% were male and 72% had bilateral DME. At baseline, visual acuity was categorized as normal/mild loss for 63.4% of patients, moderate loss for 10.4%, and severe loss/nearly blind for 26.2%. Mean 6-month DME-related costs/patient were as follows: all patients (n = 135), $ 2,092; normal/mild loss (n = 88), $ 1,776; moderate loss (n = 13), $ 1,845; and severe loss/nearly blind (n = 34), $ 3,007. Composite scores for vision-related quality of life declined with increasing visual acuity loss; generic quality of life scores were highest for moderate loss and lowest for severe loss/nearly blind. Conclusions. DME-related costs in the Canadian healthcare system are substantial. Costs increased and vision-related quality of life declined with increasing visual acuity severity.
引用
收藏
页数:9
相关论文
共 28 条
[1]  
[Anonymous], 2009, COST VISION LOSS CAN
[2]  
[Anonymous], 2008, PREF PRACT PATT GUID
[3]  
[Anonymous], 2013, CONS PRIC IND
[4]  
[Anonymous], 2009, An economic tsunami, the cost of diabetes in Canada
[5]   Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography [J].
Browning, DJ ;
McOwen, MD ;
Bowen, RM ;
O'Marah, TL .
OPHTHALMOLOGY, 2004, 111 (04) :712-715
[6]  
Cheung K., 2009, User Guide: Basic information on how to use EQ-5D
[7]   Diabetic retinopathy and diabetic macular edema - Pathophysiology, screening, and novel therapies [J].
Ciulla, TA ;
Amador, AG ;
Zinman, B .
DIABETES CARE, 2003, 26 (09) :2653-2664
[8]   Burden of illness of neovascular age-related macular degeneration in Canada [J].
Cruess, Alan ;
Zlateva, Gergana ;
Xu, Xiao ;
Rochon, Sophie .
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2007, 42 (06) :836-843
[9]   The Impact of Diabetic Retinopathy and Diabetic Macular Edema on Health-Related Quality of Life in Type 1 and Type 2 Diabetes [J].
Fenwick, Eva K. ;
Xie, Jing ;
Ratcliffe, Julie ;
Pesudovs, Konrad ;
Finger, Robert P. ;
Wong, Tien Y. ;
Lamoureux, Ecosse L. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2012, 53 (02) :677-684
[10]   Vision-related quality of life in patients with diabetic macular oedema [J].
Hariprasad, S. M. ;
Mieler, W. F. ;
Grassi, M. ;
Green, J. L. ;
Jager, R. D. ;
Miller, L. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (01) :89-92